For the Quarter Ending June 2025
North America
• In April 2025, the Biotin 98% Pure Spot Price averaged USD 180,000/MT (FOB Illinois), reflecting a soft Price Index due to weak export momentum and limited domestic inquiries from the pharmaceutical and dietary supplement sectors.
• Domestic biotin demand outlook remained sluggish as manufacturers in nutraceuticals adopted a wait-and-watch approach, leading to excess supply and discounted selling strategies.
• The biotin production cost trend was relatively stable in April, but sellers struggled with inventory pressure due to reduced overseas orders and conservative procurement from key buyers.
• In May 2025, the Spot Price climbed modestly to USD 181,000/MT, as the Price Index saw support from inflation-led input costs and marginal improvement in domestic offtake.
• Manufacturers raised prices slightly to offset cost burdens despite continued weakness in export channels; stable local consumption supported the Price Index rebound.
• By the end of May, consistent purchasing from pharmaceutical and supplement sectors allowed the market to hold firm around the USD 181,000–181,400/MT range.
• In June 2025, the Price Index fell again to USD 180,050/MT, as both export and domestic demand weakened further amid cautious buying and muted seasonal pull.
• A bearish biotin price forecast emerged by late June due to subdued downstream procurement, balanced inventories, and lack of significant movement in manufacturing sentiment.
• Despite stable production, the biotin demand outlook in personal care and animal nutrition segments remained limited, keeping price growth constrained throughout June.
• In July 2025, Biotin prices are expected to increase, driven by seasonal uptick in personal care and supplement manufacturing, alongside restocking ahead of the back-to-school period, prompting buyers to frontload orders and moderately replenish inventories.
APAC
• In April, the biotin 98% pure FOB Qingdao spot price rose to USD 166,130/MT, supported by low inventories and modestly improving factory output; the Price Index reflected firm sentiment amid trade policy uncertainties.
• Domestic restocking ahead of scheduled maintenance, coupled with strong overseas interest, created short-term pressure on supply, influencing a steady product demand outlook.
• By May, the spot price climbed further to USD 168,000/MT as domestic consumption from nutritional supplement and food additive sectors remained robust; Southeast Asian and European buyers diversified sourcing amid North American trade slowdowns.
• Chinese manufacturers balanced output with demand, maintaining a cautious stance in May, which stabilized the Price Index and supported a consistent product production cost trend.
• In June, the spot price edged down to USD 167,750/MT, as international orders softened and domestic consumption alone could not fully offset reduced export activity.
• The Biotin Price Index showed minimal movement in June, reflecting a neutral market with no major disruptions; lean inventory strategies among buyers kept bulk purchases restrained.
• Suppliers adjusted prices modestly in June to stimulate movement, but the market overall remained conservative.
• While logistics and production operations ran smoothly, end-use sectors operated with reduced urgency, leading to slight inventory buildup.
• As supply began to outpace demand toward late June, stockpiles increased across production hubs, shifting sentiment downward.
• In July 2025, the biotin price forecast suggests a likely Price Index decline as both domestic and overseas buyers limit procurement activity in response to overstocked inventories and subdued sector growth.
Europe
• The Price Index for Biotin 98% Pure in Germany rose from USD 166,230/MT in April to USD 168,085/MT in May, before slightly dropping to USD 167,860/MT in June, signaling a Q2 gain followed by a minor correction.
• In April, a stronger euro and efficient supply logistics supported stable product spot price trends, enabling cost-effective imports and minimizing volatility.
• The Biotin demand outlook was supported by seasonal uptick from pharmaceutical and nutraceutical sectors, prompting moderate inventory restocking.
• May’s Price Index gain reflected port congestion and holiday backlogs, reinforcing steady demand and creating mild upward pressure on product spot price.
• The rerouting of U.S.-bound cargo to Europe due to tariff shifts slightly tightened local supplies, influencing product price forecast trajectories mid-quarter.
• Easing inflation (CPI at 2.1% in April) encouraged proactive procurement by buyers in Germany, underpinning the product demand outlook for Biotin.
• Suppliers remained cautious in May, adopting conservative stock positions amidst logistical bottlenecks.
• June witnessed a soft pullback in product spot price to USD 166,125/MT amid steady raw material flows and unchanged product production cost trend.
• A 12-week stability in upstream supply and pricing led to subdued market sentiment, reflected in June’s near-flat Price Index.
• For July 2025, Biotin prices in Germany are likely to decline slightly, as port congestion at Hamburg and Bremerhaven limits fluid trade, while buyers prioritize existing stock depletion.
For the Quarter Ending March 2025
North America
In Q1 2025, Biotin prices in the U.S. followed a downward trajectory after a brief rise in late January. The quarter began with stable supply-demand dynamics, supported by consistent procurement from downstream industries, which helped maintain market momentum.
However, as February progressed, buyer sentiment turned cautious. Downstream manufacturers began adjusting inventory levels and delayed fresh purchases in anticipation of potential price adjustments. This shift in behavior resulted in reduced buying activity, even though manufacturing operations remained steady.
The cautious trend intensified through March, as both domestic and international demand softened. Export activity declined due to stockpiling by overseas buyers amid trade-related uncertainties. At the same time, domestic buyers—particularly in the pharmaceutical and dietary supplement sectors—adopted a conservative approach to procurement. The combination of subdued demand and sufficient supply led to mounting inventories and weaker price support.
Overall, the quarter was defined by restrained market activity, a preference for inventory drawdowns over new purchases, and a gradual price decline across the U.S. Biotin market.
Asia Pacific
In Q1 2025, Biotin prices in China displayed a fluctuating yet upward-leaning trajectory. January saw a steady rise in prices, supported by robust demand from the pharmaceutical and dietary supplement sectors. Pre-Lunar New Year stockpiling by traders and end-users contributed to price gains, while manufacturers maintained elevated production to meet both domestic and export needs. However, February marked a brief market correction. As production normalized post-holiday and inventory levels improved, prices declined due to eased supply-side pressures and cautious buyer sentiment, especially from the animal feed and nutraceutical segments. By early March, the market reversed course, with Biotin prices rising again amid renewed procurement from nutraceutical and personal care industries. Persistent supply chain constraints and heightened downstream demand placed upward pressure on prices. Market participants closely monitored inventory strategies amid tightening availability. Overall, the quarter ended with Biotin prices trending higher compared to the start of the year, shaped by seasonal supply shifts, strategic stockpiling, and consistent global demand. The market outlook remained cautiously optimistic, driven by the dual influence of recovering production and sustained end-use sector momentum.
Europe
In Q1 2025, Biotin prices in Germany followed a gradually declining trend. Early in the quarter, prices experienced a modest increase due to steady demand from key sectors such as cosmetics, dietary supplements, and pharmaceuticals. Buyers, wary of potential supply chain risks linked to the Chinese Lunar New Year, engaged in cautious restocking to ensure inventory availability. However, as February unfolded, supply concerns eased and logistics across Asia-Europe routes began to normalize. This shift, combined with previously accumulated stock, led to reduced urgency in procurement. By March, the market witnessed increased price pressure due to ample inventories and subdued buying activity. Economic and political uncertainties in Europe prompted a conservative approach among market participants, with many opting to delay purchases in anticipation of more favorable pricing. While end-user demand held steady, competitive dynamics among suppliers intensified, resulting in price adjustments to maintain market share. Overall, the German Biotin market in Q1 reflected a transition from preemptive stocking to a more restrained purchasing strategy, shaped by improved supply conditions, cautious sentiment, and softening short-term demand across downstream sectors.
For the Quarter Ending December 2024
North America
In Q4 2024, Biotin prices in the USA remained relatively stable despite various economic and market pressures. At the start of October, prices held steady as U.S. consumer sentiment showed signs of improvement with easing inflation. However, this had minimal impact on Biotin pricing. The market balanced consistent demand with a recent increase in imports, while concerns over potential shipping disruptions from a port worker strike and geopolitical tensions in the Red Sea did not significantly affect prices.
In November, a slight increase in Biotin prices was observed, driven by a modest rise in demand from end-user sectors. Additionally, some disruptions at East Coast ports due to labor strikes caused temporary delays in Biotin distribution, exerting slight pressure on supply. This created minor competition among buyers for available stocks. Despite these factors, the overall market remained stable, with typical seasonal pricing adjustments contributing to the modest upward pressure on prices.
By December, Biotin prices experienced a slight decrease as demand from end-user industries softened, influenced by persistent inflation and high interest rates. The stronger U.S. dollar also made imports cheaper, ensuring a steady supply of Biotin. The resolution of logistics challenges, particularly the ILA strike, further facilitated smoother supply chains, allowing U.S. importers to benefit from reduced shipping costs. This contributed to the overall stabilization of supply and a minor decrease in prices.
Asia Pacific
In Q4 2024, Biotin prices in China experienced significant fluctuations, influenced by both domestic and global factors. At the start of the quarter, prices surged due to strong domestic demand, driven in part by pre-Golden Week stockpiling and reduced production during the holiday period. International supply chain disruptions, including geopolitical tensions in the Middle East and US port strikes, further constrained supply, contributing to higher prices.
In early November, Biotin prices saw another increase, supported by a rebound in China’s manufacturing sector. Government stimulus measures and a weakened yuan boosted export demand, particularly for Biotin, further propelling prices upward. However, by December, the market shifted as domestic demand began to wane, particularly from the pharmaceutical and nutraceutical sectors. High distributor inventory levels led to an oversupply, which, combined with weak international demand—especially from key markets like the US and Europe—put downward pressure on prices.
The global decline in crude oil prices also played a role in lowering production costs, which contributed to the overall decrease in Biotin prices toward the end of the quarter. Manufacturers adjusted their pricing strategies to stay competitive amidst the oversupply, leading to a final drop in prices by December. Overall, Q4 2024 saw Biotin prices follow a pattern of early increases, followed by a steady decline driven by softer demand and an oversupply in the market.
Europe
In Q4 2024, Biotin prices in Germany experienced significant fluctuations, shaped by a variety of economic and logistical factors. In October, prices saw an initial increase, driven by improved consumer sentiment, lower inflation, and expectations of interest rate cuts from the European Central Bank (ECB). These factors, alongside pre-Golden Week stockpiling and ongoing disruptions in the Red Sea shipping lanes, led to heightened demand and upward pressure on prices.
November saw continued price surges as optimism surrounding the ECB’s rate cuts and expectations of economic recovery bolstered market sentiment. Suppliers, anticipating slower trade during the Christmas period, began stockpiling inventory, further inflating prices. Supply chain issues also added to the upward price trend, with delays at Hamburg's ports and extended shipping times around the Cape of Good Hope exacerbating the pressure on supply.
However, by early December, Biotin prices began to decline. This shift was driven by weaker demand from key sectors like pharmaceuticals and nutraceuticals, as well as a decrease in inflationary concerns. A 1.9% drop in energy prices contributed to reduced operational costs, allowing suppliers to lower prices and remain competitive. Additionally, well-maintained inventories helped stabilize the market as it approached the year-end. By the close of Q4, the market had become more stable, reflecting the balancing of supply and demand amid a more cautious economic outlook.
For the Quarter Ending September 2024
North America
In the third quarter of 2024, the North American Biotin market exhibited a fluctuating pricing trajectory, influenced by a variety of factors affecting different sectors. The USA, in particular, experienced the most pronounced price changes, resulting in an unstable pricing environment marked by notable fluctuations throughout the quarter.
Initially, prices declined due to a combination of factors that created downward pressure on the market. One major influence was the inflation rate, which had surged beyond 9% but began to cool significantly as the quarter progressed. This reduction in inflation led to lower overall overhead costs for businesses, allowing them to pass on these savings to consumers in the form of reduced Biotin prices. However, as the quarter drew to a close in September, a shift occurred, and prices began to surge. This increase was fueled by a confluence of economic and logistical factors. Consumer confidence rose, driven by improved perceptions of the economy and inflation, despite ongoing concerns about the labor market. This newfound optimism resulted in heightened demand for Biotin, placing upward pressure on prices.
In response to these shifting dynamics, market participants proactively increased their inventories, anticipating a rise in future demand and seeking to mitigate the potential impacts of supply chain challenges. As a result, the quarter concluded with Biotin 98% Pure priced at USD 193,000 per metric ton on an FOB Illinois basis in the USA.
Asia Pacific
During the third quarter of 2024, the Biotin market in the APAC region exhibited a mixed pricing trend influenced by a variety of factors. Initially, prices experienced a decline in July and August, primarily due to weak consumption both domestically and internationally. The Chinese market, in particular, faced a downturn early in the quarter, struggling with limited support from downstream sectors. Furthermore, escalating freight costs resulting from disruptions in global maritime traffic significantly dampened international demand, creating additional pressure on pricing. However, as the quarter progressed and approached its conclusion, prices began to rebound. This resurgence was fueled by robust demand from end-user industries and effective inventory management strategies employed by manufacturers and suppliers. Additionally, global economic recovery efforts played a critical role in driving prices upward. As industries adjusted to the ongoing conflict in the Red Sea, international demand for Biotin began to recover, further contributing to the positive momentum in pricing. In China specifically, the market experienced notable price fluctuations throughout the quarter, reflecting the sensitive interplay between supply and demand dynamics. This volatility underscored the challenges faced by market participants in navigating an ever-changing landscape. By the end of the quarter, the price for Biotin reached USD 138880 per metric ton for Biotin 98% Pure FOB Qingdao basis, signaling a more optimistic outlook for the region's pricing environment moving forward.
Europe
Throughout the third quarter of 2024, the Biotin pricing landscape in the European region displayed a diverse trend shaped by several key factors. Initially, prices experienced a decline, largely attributed to weaker-than-expected demand in the German market, especially within the nutraceutical and healthcare sectors. In light of this lack of demand, market participants adopted a cautious approach, opting to maintain substantial inventory levels to meet the current consumption needs in Germany. However, as September approached, a noticeable shift occurred, with prices beginning to rise. This uptick was driven by a combination of strong demand from end-user industries, strategic inventory management practices by companies preparing for potential disruptions, and favorable macroeconomic conditions. The ongoing conflict in the Red Sea complicated matters further by disrupting global maritime traffic, which led to logistical challenges and restricted the supply of Biotin. These supply constraints added upward pressure on prices as market dynamics evolved. In addition, improvements in consumer sentiment, particularly in Germany, played a vital role in revitalizing demand and cultivating a more optimistic market outlook. Despite the various challenges faced by the industry, companies proactively worked to enhance their stockpiles in anticipation of potential shipping delays, thereby supporting the upward trend in prices. As the third quarter drew to a close, Biotin 98% Pure was priced at USD 157,000 per metric ton on a CFR Hamburg basis in Germany, reflecting an overall positive pricing environment and a sense of stability in market sentiment.
FAQs
1. Why did Biotin prices in North America fluctuate across Q2 2025?
Biotin prices in North America started soft in April due to excess inventory and weak demand from pharmaceutical and nutraceutical sectors. The Price Index briefly recovered in May as manufacturers passed on inflationary input costs, but June saw a dip again due to continued caution among buyers and subdued seasonal pull. Despite steady production, lackluster demand in personal care and animal nutrition segments weighed on pricing momentum.
2. What factors drove Biotin price movement in China during Q2 2025?
Chinese Biotin prices strengthened in April and May, supported by tight supply and steady restocking. Buyers from Southeast Asia and Europe increased sourcing amid slower U.S. activity. However, by June, exports tapered and domestic demand alone couldn’t sustain the momentum, leading to a slight drop in the Price Index. Inventory buildup toward the end of the quarter led to muted sentiment and a weaker price outlook for July.
3. How did European Biotin prices behave throughout the quarter?
Germany’s Biotin Price Index climbed from April to May, helped by a strong euro, stable logistics, and firm demand from pharma and supplement manufacturers. U.S. trade shifts redirected some volumes to Europe, tightening local supply. However, prices softened slightly in June as raw material inflow normalized and buyers paused for stock drawdowns. July is expected to bring further mild declines amid lingering port congestion and cautious procurement.
4. Which sectors influenced global Biotin demand trends in Q2 2025?
Across all regions, the dietary supplement and pharmaceutical sectors were key demand drivers. In China, food additive applications remained resilient. In Europe, seasonal restocking boosted pharma consumption in Q2. However, personal care and animal nutrition segments underperformed, especially in North America, where demand recovery remained sluggish throughout the quarter.
